FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Domenica Lorusso

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Cristina Sigismondi; Marco Marinaccio; Francesco Raspagliesi; Enrico Breda; Massimo Candiani; Gennaro Cormio; Angiolo Gadducci; Domenica Lorusso; giorgia mangili
Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
Gabriella Ferrandina; Gilda Fuoco; Domenica Lorusso; Giovanna Mantegna; Andrea Marcellusi; Cristina Moruzzi; Marco Petrillo; Serena Terzano; Laura Venditti; Giovanni Scambia
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study.
Alessia Di Legge; Maria Cristina Moruzzi; Adele Pesce; Giovanni Scambia; Ilaria Nausica Trivellizzi; Domenica Lorusso
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Domenica Lorusso (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Cristina Sigismondi; Marco Marinaccio; Francesco Raspagliesi; Enrico Breda; Massimo Candiani; Gennaro Cormio; Angiolo Gadducci; Domenica Lorusso; giorgia mangili
Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
Gynecologic oncology 2012;125(3):673-6.
2012: Gabriella Ferrandina; Gilda Fuoco; Domenica Lorusso; Giovanna Mantegna; Andrea Marcellusi; Cristina Moruzzi; Marco Petrillo; Serena Terzano; Laura Venditti; Giovanni Scambia
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study.
Gynecologic oncology 2012;124(3):389-94.
2011: Alessia Di Legge; Maria Cristina Moruzzi; Adele Pesce; Giovanni Scambia; Ilaria Nausica Trivellizzi; Domenica Lorusso
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(8):1446-51.
2011: Sandro Pignata; Claudio Pisano; W Rasch; Giovanni Scambia; Roberto Sorio; F Amant; Enrico Breda; L Cannella; K Hernes; K Leunen; Domenica Lorusso; I Vergote
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
Cancer chemotherapy and pharmacology 2011;68(5):1347-53.
2011: giorgia mangili; Paolo Scollo; Cristina Sigismondi; Saverio Tateo; Massimo Candiani; Gennaro Cormio; Gabriella Ferrandina; Angiolo Gadducci; Stefano Greggi; Domenica Lorusso
Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(8):1414-21.
2011: Sandro Pignata; Carmela Pisano; Alberto Ravaioli; Vanda Salutari; Antonella Savarese; Laura Scaltriti; Giovanni Scambia; Paolo Scollo; Roberto Sorio; Stefano Tamberi; Maria Rosaria Valerio; Enrico Aitini; Alba Brandes; Enrico Breda; Pietro Del Medico; Massimo Di Maio; Antonio Febbraro; Gabriella Ferrandina; Antonella Ferro; Luigi Frigerio; Ciro Gallo; Vittorio Gebbia; Stefano Greggi; Francesco Legge; Alessandra Vernaglia Lombardi; Domenica Lorusso; Alessandro Morabito; Pietro Musso; Donato Natale; Francesco Perrone
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(27):3628-35.
2011: Domenica Lorusso; S Mainenti; P Malaguti; Valeria Masciullo; A Pietragalla; E Fusco; Giovanni Scambia
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
Oncology 2011;80(5-6):390-4.
2010: Domenica Lorusso; Antonella Pietragalla; Sara Mainenti; Alessia Di Legge; Giulia Amadio; Giovanni Scambia
Emerging drugs for ovarian cancer.
Expert opinion on emerging drugs 2010;15(4):635-52.
2010: Domenica Lorusso; S Mainenti; G Ferrandina; G Scambia
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
Expert review of anticancer therapy 2010;10(7):987-91.
2010: Domenica Lorusso; Antonella Pietragalla; Sara Mainenti; Valeria Masciullo; Giovanni Di Vagno; Giovanni Scambia
Review role of topotecan in gynaecological cancers: current indications and perspectives.
Critical reviews in oncology/hematology 2010;74(3):163-74.
2010: Valeria Masciullo; S Mainenti; Domenica Lorusso; Pasquale Alessandro Margariti; Giovanni Scambia
Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature.
Obstetrics and gynecology international 2010;2010():.
2010: Domenica Lorusso; Gabriella Ferrandina; Sandro Pignata; Manuela Ludovisi; R Viganò; S Scalone; P Scollo; Enrico Breda; A Pietragalla; Giovanni Scambia
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(1):61-6.
2009: Domenica Lorusso; Sara Mainenti; Antonella Pietragalla; Gabriella Ferrandina; Gilda Foco; Valeria Masciullo; Giovanni Scambia
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
Expert opinion on investigational drugs 2009;18(12):1939-46.
2009: Francesco Deodato; Gabriella Macchia; Luca Grimaldi; Gabriella Ferrandina; Domenica Lorusso; Vanda Salutari; SAVINO CILLA; Vincenzo Valentini; Numa Cellini; Angelo Piermattei; Giovanni Scambia; Alessio Giuseppe Morganti
Stereotactic radiotherapy in recurrent gynecological cancer: a case series.
Oncology reports 2009;22(2):415-9.
2008: Gabriella Ferrandina; Manuela Ludovisi; Domenica Lorusso; Sandro Pignata; Enrico Breda; Antonella Savarese; Pietro Del Medico; Laura Scaltriti; Dionyssios Katsaros; Domenico Priolo; Giovanni Scambia
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):890-6.
2008: Anna Fagotti; Francesco Fanfani; C Rossitto; Domenica Lorusso; A M De Gaetano; Antonio Giordano; Giuseppe Vizzielli; Giovanni Scambia
A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Oncology 2008;75(3-4):152-8.
2007: Gabriella Ferrandina; Manuela Ludovisi; Rosa De Vincenzo; Vanda Salutari; Domenica Lorusso; M Colangelo; T Prantera; M R Valerio; Giovanni Scambia
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(8):1348-53.
2007: Domenica Lorusso; A Di Stefano; V Carone; Anna Fagotti; Salvatore Pisconti; Giovanni Scambia
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(7):1159-64.
2007: Sandro Pignata; Giovanni Scambia; Claudio Pisano; Enrico Breda; Massimo Di Maio; Stefano Greggi; Gabriella Ferrandina; Domenica Lorusso; V Zagonel; Antonio Febbraro; N Riva; V De Rosa; Ciro Gallo; Francesco Perrone
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
British journal of cancer 2007;96(11):1639-43.
2007: Domenica Lorusso; Gabriella Ferrandina; Francesco Fanfani; Maria Lucia Gagliardi; Giovanni Scambia
Investigational agents against platinum-resistant ovarian cancer.
Expert opinion on investigational drugs 2007;16(3):325-36.
2007: Domenica Lorusso; Gabriella Ferrandina; L Pagano; Maria Lucia Gagliardi; Giovanni Scambia
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery.
Oncology 2007;72(3-4):261-4.
2006: Gabriella Ferrandina; Mariagrazia Distefano; Daniela Smaniotto; Alessio Giuseppe Morganti; Amelia Paglia; Gabriella Macchia; Barbara Corvari; Domenica Lorusso; Giovanni Scambia
Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.
Gynecologic oncology 2006;103(2):500-5.
2006: Francesco Fanfani; Giorgia Garganese; Anna Fagotti; Domenica Lorusso; Maria Lucia Gagliardi; Marco Rossi; Marzia Salgarello; Giovanni Scambia
Advanced vulvar carcinoma: is it worth operating? A perioperative management protocol for radical and reconstructive surgery.
Gynecologic oncology 2006;103(2):467-72.
2006: Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Alfredo Ercoli; Domenica Lorusso; Marco Rossi; Giovanni Scambia
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.
Annals of surgical oncology 2006;13(8):1156-61.
2006: Domenica Lorusso; A Di Stefano; Francesco Fanfani; Giovanni Scambia
Role of gemcitabine in ovarian cancer treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v188-94.
2006: Gabriella Ferrandina; Franco O Ranelletti; Francesco Legge; Vanda Salutari; Enrica Martinelli; Andrea Fattorossi; Domenica Lorusso; Gian Franco Zannoni; Valerio Gaetano Vellone; Amelia Paglia; Giovanni Scambia
Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2055-60.
2005: Domenica Lorusso; Gabriella Ferrandina; Erika Fruscella; L Marini; V Adamo; Giovanni Scambia
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1002-13.
2005: Francesco Fanfani; Anna Fagotti; Gabriella Ferrandina; Giuseppe Bifulco; Francesco Legge; Domenica Lorusso; Luca Minelli; Giovanni Scambia
Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis.
Human reproduction (Oxford, England) 2005;20(10):2964-8.
2005: Gabriella Ferrandina; Ida Paris; Manuela Ludovisi; Giuseppe D'Agostino; Antonia Testa; Domenica Lorusso; Mariangela Zanghi; Salvatore Pisconti; Giuseppa Pezzella; Vincenzo Adamo; Enrico Breda; Giovanni Scambia
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Gynecologic oncology 2005;98(2):267-73.
2005: Gabriella Ferrandina; Domenica Lorusso; R Longo; Antonia Carla Testa; G Scambia
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma.
Gynecologic oncology 2005;98(2):332-3.
2004: Domenica Lorusso; Gabriella Ferrandina; R Lo Voi; Anna Fagotti; Giovanni Scambia
Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():98-103.
2004: Antonia Carla Testa; Donata Mansueto; Domenica Lorusso; Erika Fruscella; Danila Basso; Giovanni Scambia; Gabriella Ferrandina
Angiographic power 3-dimensional quantitative analysis in gynecologic solid tumors: feasibility and reproducibility.
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2004;23(6):821-8.
2004: Domenica Lorusso; A Naldini; A Testa; Giuseppe D'Agostino; Giovanni Scambia; Gabriella Ferrandina
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
Oncology 2004;67(3-4):243-9.
2003: G D'Agostino; Gabriella Ferrandina; Manuela Ludovisi; A Testa; Domenica Lorusso; N Gbaguidi; Enrico Breda; Salvatore Mancuso; Giovanni Scambia
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
British journal of cancer 2003;89(7):1180-4.
2003: Domenica Lorusso; Gabriella Ferrandina; Stefano Greggi; Angiolo Gadducci; Sandro Pignata; S Tateo; Rosalbino Biamonte; Luigi Manzione; Giovanni Di Vagno; F Ferrau'; Giovanni Scambia
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(7):1086-93.
2002: Giuseppe D'Agostino; Gabriella Ferrandina; Giorgia Garganese; M Giovanna Salerno; Domenica Lorusso; M Giuseppina Farnetano; Salvatore Mancuso; Giovanni Scambia
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.
Oncology 2002;62(2):110-4.
2001: Stefano Greggi; M G Salerno; Giuseppe D'Agostino; Gabriella Ferrandina; Domenica Lorusso; Luigi Manzione; Salvatore Mancuso; Giovanni Scambia
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Oncology 2001;60(1):19-23.
2000: Stefano Greggi; Giuseppe D'Agostino; Daniela Smaniotto; D Genovesi; Domenica Lorusso; Giovanni Scambia
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer.
Gynecologic oncology 2000;78(1):76-7.